ATE402926T1 - Substituierte pyrazole als ppar-agonisten - Google Patents

Substituierte pyrazole als ppar-agonisten

Info

Publication number
ATE402926T1
ATE402926T1 AT04818779T AT04818779T ATE402926T1 AT E402926 T1 ATE402926 T1 AT E402926T1 AT 04818779 T AT04818779 T AT 04818779T AT 04818779 T AT04818779 T AT 04818779T AT E402926 T1 ATE402926 T1 AT E402926T1
Authority
AT
Austria
Prior art keywords
ppar agonists
substituted pyrazoles
pyrazoles
substituted
ppar
Prior art date
Application number
AT04818779T
Other languages
English (en)
Inventor
N E Faucher
Paul Martres
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0326747A external-priority patent/GB0326747D0/en
Priority claimed from GB0329462A external-priority patent/GB0329462D0/en
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Application granted granted Critical
Publication of ATE402926T1 publication Critical patent/ATE402926T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT04818779T 2003-11-17 2004-11-15 Substituierte pyrazole als ppar-agonisten ATE402926T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0326747A GB0326747D0 (en) 2003-11-17 2003-11-17 Chemical compounds
GB0329462A GB0329462D0 (en) 2003-12-19 2003-12-19 Chemical compounds

Publications (1)

Publication Number Publication Date
ATE402926T1 true ATE402926T1 (de) 2008-08-15

Family

ID=34621661

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04818779T ATE402926T1 (de) 2003-11-17 2004-11-15 Substituierte pyrazole als ppar-agonisten

Country Status (9)

Country Link
US (1) US20080021030A1 (de)
EP (1) EP1685113B1 (de)
JP (1) JP2007511485A (de)
AR (1) AR046625A1 (de)
AT (1) ATE402926T1 (de)
DE (1) DE602004015498D1 (de)
ES (1) ES2311179T3 (de)
TW (1) TW200526588A (de)
WO (1) WO2005049578A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2006004027A1 (ja) * 2004-07-01 2008-04-24 第一製薬株式会社 ピラゾール誘導体
JPWO2006090920A1 (ja) * 2005-02-28 2008-07-24 日本ケミファ株式会社 ペルオキシソーム増殖剤活性化受容体δの活性化剤
JP5237799B2 (ja) * 2005-06-27 2013-07-17 エグゼリクシス パテント カンパニー エルエルシー ピラゾールベースのlxrモジュレーター
NZ572268A (en) 2006-04-18 2011-09-30 Nippon Chemiphar Co Activating agent for peroxisome proliferator activated receptor delta (ppar)
CN101679297B (zh) 2006-12-08 2012-01-11 埃克塞利希斯股份有限公司 Lxr和fxr调节剂
WO2008125600A2 (en) * 2007-04-11 2008-10-23 Glaxo Group Limited Pyrazole derivatives as p2x7 modulators
BRPI0911197A2 (pt) 2008-04-15 2015-10-13 Nippon Chemiphar Co composto, ativador de receptor ativado pelo proliferador de peroxissoma, e, medicamento para o tratamento e /ou profilaxia de uma doença.
BRPI0921097B8 (pt) * 2008-11-21 2021-05-25 Raqualia Pharma Inc composto ou seu sal farmaceuticamente aceitável, intermediário do composto, composição farmacêutica e uso do composto
US20110034469A1 (en) 2009-08-04 2011-02-10 Takeda Pharmaceutical Company Limited Heterocyclic Compound
CN102753531B (zh) * 2009-12-15 2015-07-01 拜尔农作物科学股份公司 制备1-烷基-/1-芳基-5-吡唑羧酸衍生物的方法
TWI508968B (zh) * 2010-02-08 2015-11-21 Biota Scient Management 用於治療呼吸道融合性病毒感染的化合物
EP2560966B1 (de) * 2010-03-30 2021-01-06 Verseon International Corporation Mehrfach substituierte aromatische verbindungen als thrombinhemmer
CN101870676B (zh) * 2010-06-24 2011-09-07 山东大学 1-(2-肟基-2-苯基乙基)-3-苯基-1h-吡唑-5-甲酸乙酯衍生物及其制备与应用
EP2970141B1 (de) 2013-03-15 2020-02-26 Verseon Corporation Halogenpyrazole als thrombinhemmer
ES2853483T3 (es) 2013-03-15 2021-09-16 Verseon Int Corporation Compuestos aromáticos multisustituidos como inhibidores de la serina proteasa
TWI636047B (zh) 2013-08-14 2018-09-21 英商卡爾維斯塔製藥有限公司 雜環衍生物
BR112017004704A2 (pt) 2014-09-17 2018-01-23 Verseon Corp composto, composição farmacêutica, e, método para tratar uma doença ou distúrbio em um indivíduo
GB201421083D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd Enzyme inhibitors
GB201421085D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd New enzyme inhibitors
US10532995B2 (en) 2015-02-27 2020-01-14 Verseon Corporation Substituted pyrazole compounds as serine protease inhibitors
RS60600B1 (sr) 2016-05-31 2020-08-31 Kalvista Pharmaceuticals Ltd Derivati pirazola kao inhibitori kalikreina plazme
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
GB201609603D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide
WO2018034901A1 (en) 2016-08-16 2018-02-22 Stealth Biotherapeutics N-carboxyanhydride-based-scale synthesis of elamipretide
WO2018224455A1 (en) 2017-06-07 2018-12-13 Basf Se Substituted cyclopropyl derivatives
IL274557B2 (en) 2017-11-29 2024-09-01 Kalvista Pharmaceuticals Ltd Dosage forms comprising a plasma kallikrein inhibitor
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
TWI805699B (zh) 2018-03-01 2023-06-21 日商日本煙草產業股份有限公司 甲基內醯胺環化合物及其用途
MX2020010433A (es) 2018-04-04 2020-10-28 Japan Tobacco Inc Compuestos de pirazol sustituidos con heteroarilo y uso farmaceutico de los mismos.
JP2021528405A (ja) * 2018-06-18 2021-10-21 ヤンセン ファーマシューティカ エヌ.ベー. RORγtのモジュレータとしてのアミド置換チアゾール
CN114206852A (zh) 2019-08-09 2022-03-18 卡尔维斯塔制药有限公司 血浆激肽释放酶抑制剂

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3621775A1 (de) * 1986-03-13 1988-01-07 Thomae Gmbh Dr K Neue substituierte thiazole und oxazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
GB9604242D0 (en) * 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
WO1999018066A1 (en) * 1997-10-02 1999-04-15 Sankyo Company, Limited Amidocarboxylic acid derivatives
PL356487A1 (en) * 1999-11-10 2004-06-28 Takeda Chemical Industries, Ltd. 5-membered n-heterocyclic compounds with hypoglycemic and hypolipidemic activity
PE20011010A1 (es) * 1999-12-02 2001-10-18 Glaxo Group Ltd Oxazoles y tiazoles sustituidos como agonista del receptor activado por el proliferador de peroxisomas humano
JP3372923B2 (ja) * 2000-02-25 2003-02-04 エヌイーシーマイクロシステム株式会社 半導体集積回路
JP4383177B2 (ja) * 2002-03-01 2009-12-16 スミスクライン ビーチャム コーポレーション hPPAR活性化剤

Also Published As

Publication number Publication date
ES2311179T3 (es) 2009-02-01
EP1685113A1 (de) 2006-08-02
TW200526588A (en) 2005-08-16
DE602004015498D1 (de) 2008-09-11
EP1685113B1 (de) 2008-07-30
US20080021030A1 (en) 2008-01-24
JP2007511485A (ja) 2007-05-10
WO2005049578A1 (en) 2005-06-02
AR046625A1 (es) 2005-12-14

Similar Documents

Publication Publication Date Title
ATE402926T1 (de) Substituierte pyrazole als ppar-agonisten
ATE517886T1 (de) Pyrazolderivate
ATE435207T1 (de) Pyridin-3-carbonsäureamidderivate als cb1-inverse agonisten
ATE352552T1 (de) Substituierte pyrazole
NO20054200D0 (no) Pyrazoler samt fremgangsmate for fremstilling derav
DE602004015724D1 (de) Diazepinoindolderivate als kinaseinhibitoren
DE602004022159D1 (de) Koaxiale schnellkupplung
ATE504559T1 (de) Arylanilinderivate als agonisten des beta2- adrenergen rezeptors
DE602004024420D1 (de) Chinazolinderivate als antitumormittel
EP2091329A4 (de) Indazol-verbindungen
ATE388937T1 (de) Agonisten des cannabinoidrezeptors
ATE421506T1 (de) Neue benzimidazolderivate
DE602004017782D1 (de) Substituierte arylpyrazole als parasitizide
DE602004019555D1 (de) Heterocyclische 7-aminoalkylidenylchinolone und -naphthyridone
ATE369358T1 (de) Substituierte benzoylderivate als herbizide
NL1027084A1 (nl) Gesubstitueerde triazoolderivaten als oxytocine-antagonisten.
DE602005015204D1 (de) Oxadiazolonderivate als ppar-delta-agonisten
DE50003445D1 (de) Substituierte benzoylpyrazole als herbizide
ATE365161T1 (de) Pyrazolverbindungen
DE602004004295D1 (de) 6-ä(substituiertes)phenylütriazolopyrimidine als antikrebsmittel
ATE281435T1 (de) Phenyl-heterocyclyl-ether-derivate als serotonin re-uptake inhibitoren
ATE394372T1 (de) G-lactamderivate als prostaglandinagonisten
ATE364601T1 (de) Substituierte pyrazolverbindungen
ATE410428T1 (de) Pyrroloä2,1-cüä1,4übenzodiazepine als vasopressin-agonisten
DE502004005180D1 (de) Stereomikroskop

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties